메뉴 건너뛰기
BioDrugs
Volumn 17, Issue 5, 2003, Pages 369-372
Atlizumab: Anti-IL-6 receptor antibody - Chugai, Anti-interleukin-6 receptor antibody - Chugai, MRA - Chugai
[No Author Info available]
Author keywords

[No Author keywords available]
Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ASPARTATE AMINOTRANSFERASE; ATLIZUMAB; CYTOSTATIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;
EID: 0142122951     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317050-00006     Document Type: Review
Times cited : (17)
References (5)
  • 1
    • 0013093506 scopus 로고    scopus 로고
    • A multi-center, randomized, double-blind, placebo-controlled trial of humanized anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis
    • Sep
    • Nishimoto N, Yoshizaki K, Miyasaka N, et al. A multi-center, randomized, double-blind, placebo-controlled trial of humanized anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum 2002 Sep; 46 Suppl.: 559
    • (2002) Arthritis Rheum , vol.46 , Issue.SUPPL. , pp. 559
    • Nishimoto, N.1    Yoshizaki, K.2    Miyasaka, N.3
  • 2
    • 0036899812 scopus 로고    scopus 로고
    • Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial
    • Dec
    • Choy EHS, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002 Dec; 46: 3143-50
    • (2002) Arthritis Rheum , vol.46 , pp. 3143-3150
    • Choy, E.H.S.1    Isenberg, D.A.2    Garrood, T.3
  • 3
    • 0142132569 scopus 로고    scopus 로고
    • A double-blind, randomised, parallel group, controlled, dose ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis
    • Jul
    • Maini R, Charisma Study Group. A double-blind, randomised, parallel group, controlled, dose ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 64
    • (2003) Ann Rheum Dis , vol.62 , Issue.1 SUPPL. , pp. 64
    • Maini, R.1
  • 4
    • 18344410191 scopus 로고    scopus 로고
    • Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo
    • May
    • Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000 May; 6 (5): 583-8
    • (2000) Nat Med , vol.6 , Issue.5 , pp. 583-588
    • Atreya, R.1    Mudter, J.2    Finotto, S.3
  • 5
    • 0033959608 scopus 로고    scopus 로고
    • Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
    • Jan 1
    • Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000 Jan 1; 95 (1): 56-61
    • (2000) Blood , vol.95 , Issue.1 , pp. 56-61
    • Nishimoto, N.1    Sasai, M.2    Shima, Y.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.